Key Points
- Insider Deborah Autor sold 7,054 shares on Dec. 17 at an average price of $36.71 for a total of $258,952.34, reducing her ownership by 53.32% to 6,175 shares (valued at $226,684.25).
- The board authorized a $250 million share repurchase plan to buy up to 3% of outstanding shares, a move that typically signals management believes the stock is undervalued.
- Hims & Hers missed EPS expectations in the quarter ($0.06 vs. $0.09 consensus) but reported revenue of $598.98 million, which beat estimates and grew 49.2% year-over-year.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Deborah Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares in the company, valued at $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Hims & Hers Health Trading Down 0.7%
Shares of HIMS opened at $34.74 on Friday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. Hims & Hers Health, Inc. has a 52-week low of $23.97 and a 52-week high of $72.98. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 64.33, a PEG ratio of 6.91 and a beta of 2.41. The business's fifty day moving average is $42.22 and its 200-day moving average is $48.68.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business's quarterly revenue was up 49.2% compared to the same quarter last year. During the same period last year, the business earned $0.32 earnings per share. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.
Hims & Hers Health announced that its board has authorized a share repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's management believes its stock is undervalued.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. KeyCorp assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a "sector weight" rating for the company. BTIG Research reaffirmed a "buy" rating and set a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Weiss Ratings reiterated a "hold (c)" rating on shares of Hims & Hers Health in a research note on Monday. Bank of America boosted their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the stock an "underperform" rating in a research report on Tuesday, November 4th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $68.00 target price on shares of Hims & Hers Health in a research report on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $45.50.
Get Our Latest Analysis on Hims & Hers Health
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its holdings in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. Invesco Ltd. increased its position in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock worth $127,237,000 after buying an additional 2,128,587 shares during the period. Clear Street LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $83,582,000. Norges Bank bought a new position in Hims & Hers Health during the second quarter worth $78,464,000. Finally, Clear Street Group Inc. acquired a new position in Hims & Hers Health in the third quarter valued at $87,372,000. 63.52% of the stock is owned by institutional investors.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
